Text size A A

News

News

Date	Title and Summary	Additional Formats
Toggle Summary Feb 9, 2018	AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2017 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced	View HTML AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2017 37.2 KB
Toggle Summary Feb 1, 2018	AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 9, 2018 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it	View HTML AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 9, 2018 14.9 KB
Toggle Summary Dec 11, 2017	AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017 GAINESVILLE, Fla., and CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that	View HTML AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017 15.1 KB
Toggle Summary Nov 7, 2017	AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2017 GAINESVILLE, Fla., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the	View HTML AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2017 38.6 KB
Toggle Summary Oct 31, 2017	AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 7, 2017 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, today	View HTML AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 7, 2017 14.6 KB
Toggle Summary Oct 6, 2017	AGTC and the Medical College of Wisconsin Announce Publication of Natural History Data Examining Foveal Cone Structure in Patients with CNGB3-associated Achromatopsia GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, and the Medical College	View HTML AGTC and the Medical College of Wisconsin Announce Publication of Natural History Data Examining Foveal Cone Structure in Patients with CNGB3-associated Achromatopsia 75.5 KB
Toggle Summary Sep 29, 2017	AGTC to Present at Upcoming Gene Therapy Conferences GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, today	View HTML AGTC to Present at Upcoming Gene Therapy Conferences 18.1 KB
Toggle Summary Sep 20, 2017	AGTC to Present at Upcoming Conferences GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, today	View HTML AGTC to Present at Upcoming Conferences 17.2 KB
Toggle Summary Sep 13, 2017	AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2017 GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare	View HTML AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2017 44.8 KB
Toggle Summary Sep 5, 2017	AGTC Appoints Matthew Feinsod, M.D. as Interim Chief Medical Officer GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the	View HTML AGTC Appoints Matthew Feinsod, M.D. as Interim Chief Medical Officer 16.2 KB

Print this page Email Alerts Download Library Share E-mail page

Visionary science for life changing cures.

Contact us Join our team